NMRA
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. (NMRA) has 4 SEC Form 4 filings (4 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Feb 19, 2026.
- Industry:Biotechnology
- CEO:Paul L. Berns
- Employees:96
- HQ:Watertown, MA, US
- IPO:2023-09-15
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$83K
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
BERNS PAUL LFirst filing | See Remarks | Sale | 9,819 | $34K | Feb 19 | SEC ↗ |
Pinto JoshuaFirst filing | President | Sale | 5,967 | $21K | Feb 19 | SEC ↗ |
Milligan Michael LeeFirst filing | See Remarks | Sale | 1,436 | $5K | Feb 19 | SEC ↗ |
Aurora Daljit SinghFirst filing | See Remarks | Sale | 6,165 | $22K | Feb 19 | SEC ↗ |
Related companies
Neumora Therapeutics, Inc. is in the Healthcare sector.